Question for anyone who thinks they have an answer: Why have I consistently heard Nevro's trial result are quite good but many patients don't get the same pain relief with their permanent implants? Thanks in advance
If you’ve spent anytime in the scs world, you would realize that your observation holds true with Stjude, Mdt and Boston, troll,
Newsflash-for whatever reasons,Nevro outcomes are NOT superior in the larger world outside the FDA. And your NVRO stock...
Numbers don’t lie, Nevro had an outstanding Qtr in spite of personal turnover. The other players in the scs space WISH they could mirror the gains. I’m in a BUY mood....
Thanks midget but your wrong yet again, the fact guidance was lowered so significantly demonstrates lack of confidence in how the company is being managed. Nevro was expected to post a loss of $0.34 per share when it actually produced a loss of $0.59, delivering a surprise of -73.53% which is why you are being downgraded. So your quarter is NOT a great quarter but a highly troubling quarter for investors. Over the last four quarters, the company has surpassed consensus EPS estimates just once and for a “high growth company” that is considered poor performance.
Everything Nevro has accomplished, since day one, has been in spite of personnel turnover. Hubris and autocratic leadership continue to hold Nevro back, and the window of new-tech hype is closing.
Obvious to anyone who has been out of neuromodulation long enough for the kool-aid to have dissipated: trials are too short to be meaningful, patient is often doped up during it, reported relief from trial is goosed by the rep and laced with 'hopium.' Plenty of people get real relief, but they're just lucky.
All the gossips left with Keith and Niamh. Everyone still here is too busy working. I’ll give you something to talk about, though: Nevro has acquired Vyrsa.
What’s going on NC? Heard they finally got rid of that idiot DS. I’m sure his little crony is still around.
